Susceptibility to hepatitis B virus infection in adults living in Spain
Abstract Background A protective hepatitis B virus (HBV) vaccine has been available for four decades. Universal HBV vaccination of infants is recommended by the WHO since the 1990s. Furthermore, HBV immunization is advised for all adults with high‐risk behaviours and no seroprotection. However, HBV vaccine coverage remains globally suboptimal. The advent of new more efficacious trivalent HBV vaccines has renewed the interest in HBV vaccination. At present, the extent of current HBV susceptibility in adults remains unknown in Spain. Methods HBV serological markers were assessed on a large and representative sample of adults in Spain, including blood donors and individuals belonging to high‐risk groups. Serum HBsAg, anti‐HBc and anti‐HBs were tested in specimens collected during the last couple of years. Results From 13 859 consecutive adults tested at seven cities across the Spanish geography, overall 166 (1.2%) had positive HBsAg. Past HBV infection was recognized in 14% and prior vaccine immunization in 24%. Unexpectedly, 37% of blood donors and 63% of persons belonging to high‐risk groups had no serum HBV markers and therefore were potentially HBV susceptible. Conclusion Roughly 60% of adults living in Spain seem to be HBV susceptible. Waning immunity might be more common than expected. Hence, HBV serological testing should be performed at least once in all adults regardless of risk exposures. HBV vaccine full courses or boosters should be administered to all adults lacking serological evidence of HBV protection..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Liver International - 43(2023), 5, Seite 1015-1020 |
| Beteiligte Personen: |
Soriano, Vicente [VerfasserIn] |
|---|
| Anmerkungen: |
© 2023 John Wiley & Sons A/S |
|---|
| Umfang: |
6 |
|---|
| doi: |
10.1111/liv.15548 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY016333616 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY016333616 | ||
| 003 | DE-627 | ||
| 005 | 20231111183014.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231111s2023 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/liv.15548 |2 doi | |
| 028 | 5 | 2 | |a 2023-11-11_LIV_2023_43_5.zip.xml |
| 035 | |a (DE-627)WLY016333616 | ||
| 035 | |a (WILEY)LIV15548 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Soriano, Vicente |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Susceptibility to hepatitis B virus infection in adults living in Spain |
| 264 | 1 | |c 2023 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 John Wiley & Sons A/S | ||
| 520 | |a Abstract Background A protective hepatitis B virus (HBV) vaccine has been available for four decades. Universal HBV vaccination of infants is recommended by the WHO since the 1990s. Furthermore, HBV immunization is advised for all adults with high‐risk behaviours and no seroprotection. However, HBV vaccine coverage remains globally suboptimal. The advent of new more efficacious trivalent HBV vaccines has renewed the interest in HBV vaccination. At present, the extent of current HBV susceptibility in adults remains unknown in Spain. Methods HBV serological markers were assessed on a large and representative sample of adults in Spain, including blood donors and individuals belonging to high‐risk groups. Serum HBsAg, anti‐HBc and anti‐HBs were tested in specimens collected during the last couple of years. Results From 13 859 consecutive adults tested at seven cities across the Spanish geography, overall 166 (1.2%) had positive HBsAg. Past HBV infection was recognized in 14% and prior vaccine immunization in 24%. Unexpectedly, 37% of blood donors and 63% of persons belonging to high‐risk groups had no serum HBV markers and therefore were potentially HBV susceptible. Conclusion Roughly 60% of adults living in Spain seem to be HBV susceptible. Waning immunity might be more common than expected. Hence, HBV serological testing should be performed at least once in all adults regardless of risk exposures. HBV vaccine full courses or boosters should be administered to all adults lacking serological evidence of HBV protection. | ||
| 700 | 1 | |a Aguilera, Antonio |4 aut | |
| 700 | 1 | |a Benito, Rafael |4 aut | |
| 700 | 1 | |a González‐Díez, Rocío |4 aut | |
| 700 | 1 | |a Miró, Elisenda |4 aut | |
| 700 | 1 | |a Liendo, Paloma |4 aut | |
| 700 | 1 | |a Rodríguez‐Diaz, Juan Carlos |4 aut | |
| 700 | 1 | |a Cabezas, Teresa |4 aut | |
| 700 | 1 | |a Richart, Alberto |4 aut | |
| 700 | 1 | |a Ramos, José Manuel |4 aut | |
| 700 | 1 | |a Barea, Luisa |4 aut | |
| 700 | 1 | |a Álvarez, Carmen |4 aut | |
| 700 | 1 | |a Treviño, Ana |4 aut | |
| 700 | 1 | |a Gómez‐Gallego, Félix |4 aut | |
| 700 | 1 | |a Corral, Octavio |4 aut | |
| 700 | 1 | |a Mendoza, Carmen |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Liver International |g 43(2023), 5, Seite 1015-1020 |w (DE-627)WLY009720367 |x 14783231 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2023 |g number:5 |g pages:1015-1020 |g extent:6 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2023 |e 5 |h 1015-1020 |g 6 | ||